# Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Source: https://onco.cc/trials/nct06992336/  
OnCo record `nct06992336` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of anlotinib, benmelstobart and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.

## Summary

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy is a phase 2, randomised interventional study registered as NCT06992336 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 411 participants, started 2025-04-10 and due to reach its primary completion in 2031-04-10. Interventions recorded: Anlotinib ,; Benmelstobart; Capecitabine. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "* TNBC patients". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06992336
- Phase: 2
- Setting: A Phase II, Open-label, Randomized Trial to Compare Anlotinib and Immunotherapy and Capecitabine Versus Investigator's Choice Therapy in High Risk ctDNA Positive, Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 411

## Sources

- ClinicalTrials.gov NCT06992336: https://clinicaltrials.gov/study/NCT06992336

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Benmelstobart](https://onco.cc/drugs/benmelstobart/), [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06992336.json